Can Hepatic-splenic Elastography Predict the Risk of Hepatocellular Recurrence After Radiofrequency Ablation?

Recruiting now

Conditions studied: HCC - Hepatocellular Carcinoma

In brief

The study aims to assess whether there is an association between hepatic and splenic elastography values and the risk of HCC recurrence after treatment with RFA

Key facts

Study ID

NCT06777017

Run by

IRCCS Azienda Ospedaliero-Universitaria di Bologna

People needed

50

Starts

2022-04-22

Expected to finish

2025-12-31

Last updated by the study team

2025-01-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical-instrumental diagnosis of chronic liver disease.
• Indication for treatment of HCC with RFA using the Barcelona Clinic Liver Cancer (BCLC staging system) classification system19;
• Performing hepatic or splenic elastography by transient method with Fibroscan® (Echosens, Paris, France) or ARFI method (ACUSON Sequoia Siemens).
• Signature of informed consent

You may not qualify if…

• Age < 18 years;
• Diagnosis of hepatocholangiocarcinoma or other hepatic focal lesions other than hepatocellular carcinoma;
• Previous history of liver transplantation (OLT) and/or liver resection for HCC in the previous two years;
• Liver disease in decompensation (Child-Pugh C) at the time of informed consent or within three months prior to enrollment;
• Patients with other severe and advanced diseases that may affect short-term mortality (e.g. further non-remission neoplasms, heart failure >NYHA III, chronic renal failure in dialysis, pulmonary diseases dependent on home oxygen therapy).

Where it is running

• IRCCS Azienda Ospedaliero - Universitaria di Bologna — Bologna, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.